

Date: 14th February, 2022

To,
Listing Department,
BSE Limited,
Floor 25, PJ Tower
Dalal Street,
Mumbai – 400 001
Script Code: 540359

Sub.: Outcome of the meeting of the Board of Directors of the Company

Dear Sirs,

In continuation of our Corporate announcement dated 7th February, 2022 we hereby inform you that the Board of Directors of the Company has, at its meeting held today, inter—alia, considered and approved:

Unaudited Financial Results for quarter and nine months ended 31st December, 2021. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and nine months ended 31st December, 2021.

Further we are submitting the Limited Review report on Unaudited Financial Results for quarter and nine months ended 31st December, 2021 issued by our Statutory Auditors i.e. M/ s. B A Shah S R Mehta & Co.

The meeting was concluded at 7.15 pm.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited


Yash J. Vora
Company Secretary



Encl: As above

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)

Statement of Standalone Unaudited Results for the Quarter & Nine Months ended 31.12.2021

(in Rs.)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	28858789	65424425	104508255	111631416	188132432	262045442
II.	Other income	55715	246515	232691	459810	654568	888608
III.	Total Income (I+II)	28914504	65670940	104740946	112091226	188787000	262934050
IV.	Expenses						
	(a) Cost of materials consumed	7737214	13679199	54127141	29526691	102576659	134117896
	(b) Purchase of stock-in-trade	0	0	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1752924	11047511	-84543	32629	-8081735	231000
	(d) Employee benefits expense	9633779	12021927	12567329	29774683	28969366	35388780
	(e) Finance Costs	1075591	994177	1154942	3003232	2985356	3542515
	(f) Depreciation and amortisation expense	4849480	4768281	5174121	14327090	14400512	19415616
	(g) Other expenses*	12551980	11753577	16433528	33552119	37360648	58153846
	Total expenses (IV)	34095120	54264672	89372518	110216446	178210806	250849653
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-5180616	11406268	15368428	1874780	10576194	12084397
VI	Exceptional Items	0	0	0	0	0	0
VII	Profit/ (Loss) before tax (V-VI)	-5180616	11406268	15368428	1874780	10576194	12084397
VIII	Tax expense:						
	(1) Current tax	0	0	0	0	0	2956207
	(2) Deferred tax	0	0	0	0	0	1,583,972
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-5180616	11406268	15368428	1874780	10576194	7544218
X	Profit/(loss) from discontinued operations				0		
XI	Tax expense of discontinued operations	0	0	0	0	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0	0	0
XIII	Profit (Loss) for the period (IX+XII)	-5180616	11406268	15368428	1874782	10576195	7544218
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0	0
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-5180616	11406268	15368428	1874782	10576195	7544218
XVI	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	37413000	37413000
XVII	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic	-1.38	3.05	4.11	0.50	2.83	2.02
	(b) Diluted						

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)



Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14.02.2022
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and nine months ended 31st December, 2021
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the quarter and nine months ended 31st December, 2021, in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

Place Hadamtala (Rajkot)
Date: 14.02.2022

FOR, PARMAX PHARMA LIMITED


Dr. Umang Gosalia
Managing Director



PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner

Malay B Shah

B.Com. F.C.A.

M. No. 159526

Partner

Zarna M Shah

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and Nine months ended ended **31st December 2021** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **14th February 2022**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there



Head Office:

209-Sapphire Complex, IInd Floor

21/25-B New Jagnath Plot,

Dr.Yagnik Road

RAJKOT- 360 001

(GUJARAT)

Branch Office:

302-Vedant Complex,

7/B Kalpana Society,

C.G.Road, Navrangpura,

AHMEDABAD - 380 009

(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149

(E) bassrmco.office@gmail.com

Or

mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner

Malay B Shah

B.Com. F.C.A.

M. No. 159526

Partner

Zarna M Shah

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 14.02.2022



For **B. A. SHAH S R MEHTA & Co.**

Chartered Accountants

FRN NO : 128796W

A handwritten signature in blue ink that reads "Malay B. Shah".

MALAY B SHAH

Partner

M. No. 159526

UDIN : 22159526ACEJGG8128

Head Office:

209-Sapphire Complex, IInd Floor

21/25-B New Jagnath Plot,

Dr.Yagnik Road

RAJKOT- 360 001

(GUJARAT)

Branch Office:

302-Vedant Complex,

7/B Kalpana Society,

C.G.Road, Navrangpura,

AHMEDABAD - 380 009

(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149

(E) bassrmco.office@gmail.com

Or

mbshah_31@hotmail.com